Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and ...
The next-generation sequencing test, infexn, developed by HaystackAnalytics, is a genomics-based test capable of detecting ...
Collaboration will support Controlled Human Infection Model (CHIM) studies to accelerate development of effective and affordable RSV vaccinesNantes, France and Heidelberg, Germany, October 8, 2024 ...
The Eastern Ontario Health Unit is advising a new treatment is now available in the region to help protect infants from the ...
Researchers from Brigham and Women’s Hospital published new research in Science Translational Medicine showing that natural ...
EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...
Pfizer has reportedly ended its Phase II/III trials for sisunatovir, a promising RSV candidate acquired with ReViral in a ...
COVID-19 disrupted established patterns of seasonal transmission for several major respiratory Illnesses, with the exception of rhinovirus.
Colorado's health department is working to get more information out to the public about circulating respiratory viruses. It’s ...
GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...
Hosted on MSN4d
What It’s Like to Have RSV as an Older AdultAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted ... You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback